2. Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
3. Has progressed on, and would no longer benefit from, endocrine therapy
4. Has been treated at least 1 prior line of chemotherapy in the metastatic setting
Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions
Receives anti-HER2 ADC treatment
Life expectancy \> 3 months
Evidence of measurable or evaluable disease (RECIST 1.1 criteria)in the 28 days before selection
ECOG ≤2
You may not be if
Has breast cancer ever assessed with high-HER2 expression
Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study
Clareo Health | HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADC
